TRVI | Trevi Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.7200 - 3.01
52 Week Range	0.9700 - 4.00
Beta	2.04
Implied Volatility	319.78%
IV Rank	30.24%
Day's Volume	387,407
Average Volume	436,857
Shares Outstanding	76,865,700
Market Cap	212,917,989
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-05-07

Valuation
Profitability
Growth
Health
P/E Ratio	-6.30
Forward P/E Ratio	N/A
EPS	-0.44
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	26
Country	USA
Website	TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

TRVI's peers: BCLI, CRBP, EQ, GLYC, RANI, TARA, LIFE, CUE, ANTX, BCAB, SPRO, BOLT, CHRS, GRCL, NLTX, FHTX, CCCC, CYT, PRLD, RZLT, LYRA, SQZ, TCON, SEER, ORIC, ANEB, CGEM, VIRX

*Chart delayed

Analyzing fundamentals for TRVI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see TRVI Fundamentals page.

Watching at TRVI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TRVI Technicals page.